Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 3/2012

01-06-2012 | ALLERGIC AND IMMUNOLOGIC DISORDERS OF THE EYE AND NERVOUS SYSTEM (CH KATELARIS, SECTION EDITOR)

Diagnostics and New Developments in the Treatment of Ocular Allergies

Authors: Osmo Kari, K. Matti Saari

Published in: Current Allergy and Asthma Reports | Issue 3/2012

Login to get access

Abstract

About 30% of people suffer from allergic symptoms, and 40% to 80% of them have eye symptoms. Atopic conjunctivitis is divided into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. The treatment of seasonal allergic conjunctivitis is simple: antihistamines, anti-inflammatory agents, or cromoglycate. Perennial allergic conjunctivitis needs longer therapy with mast cell stabilizers and sometimes local steroids. Atopic keratoconjunctivitis requires long-term treatment of the lid eczema and keratoconjunctivitis. Vernal keratoconjunctivitis mainly affects children and young people. It commonly calms down after puberty. It demands intensive therapy, often for many years, to avoid serious complicating corneal ulcers. Giant papillary conjunctivitis is a foreign body reaction in contact lens users or patients with sutures following ocular surgery. Nonallergic eosinophilic conjunctivitis affects mostly middle-aged and older women with eosinophilic conjunctivitis and dry eye. Contact allergic blepharoconjunctivitis is often caused by cosmetics and eye medication. Work-related ocular allergies should be considered as a cause of resistant ocular symptoms in workplaces.
Literature
1.
Key B. Allergy and allergic diseases. Part I N Engl J Med. 2001;344:30–7.
2.
Ono SJ, Abelson MB. Allergic conjunctivitis update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol. 2005;115:118–22.PubMedCrossRef
3.
Hussain A, Awan H, Khan MD. Prevalence of non-vision-impairing conditions in a village in Chakwal district, Punjab, Pakistan. Ophthal Epidemiol. 2004;11(5):413–26.CrossRef
4.
5.
Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol. 2008;153 Suppl 1:17–21.PubMedCrossRef
6.
•• Ibáñez MD, Garde JM. Allergy in patients under fourteen years of age in Alergológica 2005. J Investig Allergol Clin Immunol. 2009;19 Suppl 2:61–8. This is a good review of allergies in childhood.PubMed
7.
Saari KM, Kari O, Haahtela T. Nonallergic eosinophilic conjunctivitis. Expert Rev Ophthalmol. 2007;2(3):331–3.CrossRef
8.
•• Kari O, Haahtela T, Laine P, Turunen JP, Kari M, Sarna S, et al. Cellular characteristics of non-allergic eosinophilic conjunctivitis. Acta Ophthalmol Scand. 2010;88(2):245–50. This is the first article to characterize the cells typically found in NAEC.
9.
•• Reitamo S, Remitz A, Haahtela T. Hit early and hit hard in atopic dermatitis and not only in asthma. Allergy. 2009;64(4):503–4. This article points out the importance of early therapy to prevent chronicity and tissue damage.PubMedCrossRef
10.
Chigbu DI. The pathophysiology of ocular allergy: a review. Cont Lens Anterior Eye. 2009;32:3–15.PubMedCrossRef
11.
12.
Ikoma A. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mechanisms and management of itch in atopic dermatitis. J Pharmacol Sci. 2009;110(3):265–9.PubMedCrossRef
13.
• Raap U, Ständer S, Metz M. Pathophysiology of itch and new treatments. Curr Opin Clin Allergy Clin Immunol. 2011;11:420–7. This article describes the mechanisms of itch and new therapeutic modalities.CrossRef
14.
•• Spencer LA, Szela CT, Perez SA, et al. Human eosinophils constitutively express multiple TH1, Th2 and immunoregulatory cytokines that are secreted rapidly and differentially. J Leukoc Biol. 2009;85(1):117–23. This paper shows present insight into the nature of preformed eosinophil cytokines and the functions of human eosinophils in mediating inflammation and initiation of specific immunity.PubMedCrossRef
15.
• Mantelli F, Lambiase A, Bonini S, Bonini S. Clinical trials in allergic conjunctivitis: a systematic review. Allergy. 2011;66:919–24. This systematic review points out the lack of good controlled treatment studies.PubMedCrossRef
16.
Kari O, Salo OP, Halmepuro L, et al. Tear histamine during allergic conjunctivitis challenge. Graefe’s Arch Clin Exp Ophthalmol. 1985;223(2):60–2.CrossRef
17.
Sacchetti M, Micera A, Lambiase A, Speranza S, Mantelli F, Petrachi G, et al. Tear levels of neuropeptides after specific allergen challenge in allergic conjunctivitis. Molecular Vision. 2011;17:47–52.PubMed
18.
Köberlein J, Kothe AC, Schaffert C. Determinants of patients compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol. 2011;11:192–9.PubMedCrossRef
19.
• Abelson MB, McLaughlin JT, Gomes PJ. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep. 2011;11:205–11. This article tells the well-known truth that there are no major differences among currently available antihistamines.PubMedCrossRef
20.
Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin. 2011;27:623–31.PubMedCrossRef
21.
Gous P, Ropo A. A comparison trial of the safety and efficacy of 0.1% percent pemiroplast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis. Ocul Pharmacol Ther. 2004;20:139–50.CrossRef
22.
Skoner D, Gentile D, Bush R, et al. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol. 2010;125(3):660–6.PubMedCrossRef
23.
Malling H-J, Montagut A, Melac M, et al. Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis. Clin Exp Allergy. 2009;39(3):387–93.PubMedCrossRef
24.
•• Canonica GW, Bousquet J, Casale T, et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009;64 Suppl 91:1–59. This article presents basic knowledge about sublingual immunotherapy.PubMed
25.
Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev. 2011;6:CD007685.
26.
Yanni JM, Barney NP. Ocular allergy: clinical, therapeutic and drug discovery consideration. In: Yorio T, Clark A, Wax M, editors. Ocular therapeutics: eye on new discoveries. USA: Elsevier; 2008.
27.
• Offiah I, Calder VL. Immune mechanisms in allergic eye diseases: what is new? Curr Opin Allergy Clin Immunol. 2009;9:477–81. This is a newer review about mechanisms in allergic eye diseases.PubMedCrossRef
28.
Reitamo S. Tacrolimus: a new topical immunomodulatory therapy for atopic dermatitis. J Allergy Clin Immunol. 2001;107(3):445–8.PubMedCrossRef
29.
Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis; a retrospective study. Acta Ophtalmol. 2006;84(5):693–5.CrossRef
30.
•• Remitz A, Virtanen HM, Reitamo S, Kari O. Tacrolimus ointment in atopic blepharoconjunctivitis does not seem to elevate intraocular pressure. Acta Ophthalmol. 2011;89(3)):e295–6. doi:10.​1111/​j.​1755-3768.​2009.​01834.​x. This is the first article to show how effective and safe tacrolimus ointment is in treating severe allergic eye disease.PubMed
31.
• Ebihara N, Ohashi Y, Uchio E, Okamoto S, Kumagai N, Shoji J, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:365–72. This article confirms the safety of topical cyclosporine drops in treatment of severe allergic eye diseases.PubMedCrossRef
32.
Kari O, Haahtela T. Is atopy a risk factor for the use of contact lenses? Allergy. 1992;47:295–8.PubMedCrossRef
33.
Kari O, Teir H, Huuskonen R, et al. Tolerance to different kinds of contact lenses in young atopic and non-atopic wearers. CLAO. 2001;27(3):151–4.
34.
Kari O, Haahtela T. Conjunctival eosinophilia in atopic and non-atopic external eye symptoms. Acta Ophthalmol. 1992;70(3):335–40.
35.
Ponikaus JU, Sherris DA, Kephart GM, et al. Features of airway remodelling and eosinophilic inflammation in chronic rhinosinusitis. J Allergy Clin Immunol. 2003;112(5):877–82.CrossRef
36.
Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchoalveolar lavages from patients with various lung diseases associated with eosinophilia. Am J Respir Crit Care Med. 1994;150(4):1038–48.PubMed
37.
Kari O. Atopic conjunctivitis. A cytologic examination. Acta Ophthalmol. 1988;66(4):381–6.
38.
Feser A, Mahler V. Periorbital dermatitis: causes, differential diagnoses and therapy. J Dtsch Dermatol Ges. 2010;8(3):159–66.PubMedCrossRef
39.
Peate WF. Work related eye injuries and illnesses. Am Family Phys. 2007;75(7):1017–22.
40.
Peltonen S, Kari O, Jarva H, et al. Complement activation in tear fluid during occupational mold challenge. Ocul Immunol Inflamm. 2008;16(5):224–9.PubMedCrossRef
41.
Kari O, Hannuksela M. Silmän yliherkkyyssairaudet. In: Haahtela T, Hannuksela M, Terho EO, editors. Allergologia. Helsinki: Kustannus Oy Duodecim; 1999. p. 203–13.
42.
Kari O, Salo OP, Björkstén F, Backman A. Allergic conjunctivitis, total and specific IgE in the tear fluid. Acta Ophthalmol. 1985;63(1):97–9.
43.
Löfstedt H, Westberg H, Seldén AI, Rublad S, Bryngelsson IL, Ngo Y, et al. Nasal and ocular effects in foundry workers using the hot box method. J Occup Environ Med. 2011;53:43–8.PubMedCrossRef
Metadata
Title
Diagnostics and New Developments in the Treatment of Ocular Allergies
Authors
Osmo Kari
K. Matti Saari
Publication date
01-06-2012
Publisher
Current Science Inc.
Published in
Current Allergy and Asthma Reports / Issue 3/2012
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-012-0252-9

Other articles of this Issue 3/2012

Current Allergy and Asthma Reports 3/2012 Go to the issue

ASTHMA (WJ CALHOUN AND J BOUSQUET, SECTION EDITORS)

The Role of Smoking in Allergy and Asthma: Lessons from the ECRHS

ALLERGIC AND IMMUNOLOGIC DISORDERS OF THE EYE AND NERVOUS SYSTEM (CH KATELARIS, SECTION EDITOR)

Migraine and Allergy: A Review and Clinical Update

ASTHMA (WJ CALHOUN AND J BOUSQUET, SECTION EDITORS)

Diagnosis of Occupational Asthma: An Update

Retraction Note

Erratum to: Treating Allergic Rhinitis in Pregnancy

ASTHMA (WJ CALHOUN AND J BOUSQUET, SECTION EDITORS)

Nutrition and Asthma

ASTHMA (WJ CALHOUN AND J BOUSQUET, SECTION EDITORS)

Recent Advances in the Epidemiologic Investigation of Risk Factors for Asthma: A Review of the 2011 Literature